Literature DB >> 28638241

Oral Anaerobic Bacteria in the Etiology of Ankylosing Spondylitis.

Mesut Öğrendik1.   

Abstract

Ankylosing spondylitis (AS) is associated with periodontitis. Anti-Porphyromonas gingivalis and anti-Prevotella intermedia antibody titers were higher in patients with spondyloarthritis than in healthy people. Sulfasalazine is an effective antibiotic treatment for AS. Moxifloxacin and rifamycin were also found to be significantly effective. The etiology hypothesis suggests that oral anaerobic bacteria such as Porphyromonas spp and Prevotella spp contribute to the disease. These bacteria have been identified in AS, and we will discuss their pathogenic properties with respect to our knowledge of the disease. Periodontal pathogens are likely to be responsible for the development of AS in genetically susceptible individuals. This finding should guide the development of more comprehensive and efficacious treatment strategies for AS.

Entities:  

Keywords:  Ankylosing spondylitis; etiology; oral bacteria

Year:  2017        PMID: 28638241      PMCID: PMC5470850          DOI: 10.1177/1179544117712992

Source DB:  PubMed          Journal:  Clin Med Insights Arthritis Musculoskelet Disord        ISSN: 1179-5441


Introduction

The term periodontal disease (PD) embraces a number of conditions in which the supporting tissues of the teeth are attached.1 Chronic adult periodontitis is the most common form of advanced PD affecting the general population, and it is a major cause of tooth loss after the age of 25 years.1 Ankylosing spondylitis (AS) and other HLA-B27–associated forms of arthritis (eg, reactive arthritis) constitute a relatively common group of arthritides (spondyloarthropathies), affecting up to 2% of White individuals.2 Epidemiologic and familial data have established a strong disease association with the HLA class I antigen B27, but they also suggest that additional genes modify both susceptibility to AS and the phenotypic expression of this disease.2 Because AS is associated with periodontitis,3 those with AS have significantly higher risks of PD.4 Ankylosing spondylitis and PD are 2 similar diseases from many aspects. The cytokine profiles are almost the same,5 and both diseases are observed in soft and hard connective tissue.4 In 2009, the Assessment of SpondyloArthritis International Society (ASAS) proposed a new terminology for spondyloarthritis (SpA) which is based on the classification criteria that changed the perspective of AS.6,7 From now on, the axial form of SpA (AxSpA) is equal to the (early) nonradiographic-type (nr-axial SpA) and radiographic-type AS (according to the older modified New York criteria).8 The advantage of the new terminology is that it includes patients with earlier and less frequent disease and reflects the severity of the spectrum that is seen in the clinical practice.

Periodontal Disease and Oral Bacteria

The causes of PD are multifactorial in that several bacterial species are involved, interacting with host tissues and cells and leading to the release of many inflammatory mediators.1 This in turn leads to the destruction of tooth-supporting structures.1 These diseases are classified into several groups. Among them, gingival diseases affect gingival tissues with no loss of attachment, whereas periodontitis is accompanied by inflammation within the supporting tissues of the teeth, attachment loss, and bone loss. It is clinically characterized by symptoms such as bleeding gums, bad breath, gingival recession, tooth mobility, and migration. Porphyromonas gingivalis is a Gram-negative, obligate anaerobic, nonmotile bacterium.1 Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia are associated with the pathogenesis of chronic periodontitis.1 The “red complex” comprises bacteria that are considered to be periodontal pathogens1 and include these 3. The red complex secretes peptidylarginine deiminases.1 This review examines the association between oral bacteria and the etiology of AS.

Periodontal Pathogens and AS

Anti–P gingivalis and anti–Prevotella intermedia antibody titers were higher in patients with SpA than in healthy people.9 Sulfasalazine is an effective antibiotic treatment for AS.10 When reviewing the literature, 8 randomized controlled studies that focused on sulfasalazine use were found10–17; however, long-term use results in drug resistance. It is more effective for the peripheral signs than the spinal symptoms of AS.17 In yet another study of 22 patients with active AS, a new treatment modality was evaluated and compared with an oral treatment.18 Rifamycin was found to be significantly effective in the treatment of AS. In yet another study, researchers used moxifloxacin—a quinolone group antibiotic used to treat anaerobic bacteria—for AS treatment in 2007.19 In this open-label study, moxifloxacin was continuously effective in treating the symptoms and clinical parameters of AS. The risk of AS in HLA-B27–positive individuals is 2% to 5%, and 90% to 95% of affected White individuals are HLA-B27 positive.2 Twenty-five subtypes of HLA-B27 have been assigned on the basis of nucleotide sequence homology; they encode 23 different products.2 The prevalence of these subtypes varies depending on ethnicity, and B*2705, followed by B*2702, is the most common subtype in Whites.2 Determination of the crystal structure of HLA*2705 and characterization of the peptide binding properties of it and other subtypes suggest a mechanism for the B27 disease association. Most naturally bound peptides eluted from B27 share arginine at position 2 that interacts with the glutamine at position 45 in the B pocket.2 These observations suggest that the B pocket may convey specificity for the binding of putative arthritogenic peptide(s). The polymorphic region of B27, spanning residues 169 to 179, demonstrates homology between bacterial proteins and one of the endogenous peptides presented in vivo by B27 in B27-transfected lymphoblastoid cell lines.2 Neither B27 transgenic rats nor B27 transgenic mice develop either intestinal inflammation or peripheral arthritis when maintained in germfree environments. Furthermore, only transgenic rats colonized with defined bacterial cocktails that contain Bacteroides spp develop intestinal inflammation.2 HLA-B27 endogenous peptides include an arginine at the second residue (Figure 1). Peptidylarginine deiminases of oral bacteria might lead to arginine degradation in HLA-B27.2
Figure 1

Antigen presentation in ankylosing spondylitis.

Conclusions

Periodontal pathogens are responsible for the development of AS in genetically susceptible individuals. This finding should guide the development of more comprehensive and efficacious treatment strategies for AS.
  16 in total

1.  Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial.

Authors:  M Nissilä; K Lehtinen; M Leirisalo-Repo; R Luukkainen; O Mutru; U Yli-Kerttula
Journal:  Arthritis Rheum       Date:  1988-09

2.  Association between ankylosing spondylitis and chronic periodontitis: a population-based study.

Authors:  Joseph J Keller; Jiunn-Horng Kang; Herng-Ching Lin
Journal:  Arthritis Rheum       Date:  2013-01

3.  Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment.

Authors:  H G Taylor; E J Beswick; P T Dawes
Journal:  Clin Rheumatol       Date:  1991-03       Impact factor: 2.980

4.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

5.  Serum cytokine levels and periodontal parameters in ankylosing spondylitis.

Authors:  U Sezer; K Erciyas; Y Pehlivan; K Ustün; M Tarakçioğlu; S Z Senyurt; A M Onat
Journal:  J Periodontal Res       Date:  2011-11-29       Impact factor: 4.419

6.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

7.  The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years.

Authors:  J Kirwan; A Edwards; B Huitfeldt; P Thompson; H Currey
Journal:  Br J Rheumatol       Date:  1993-08

8.  Treatment of ankylosing spondylitis with moxifloxacin.

Authors:  Mesut Ogrendik
Journal:  South Med J       Date:  2007-04       Impact factor: 0.954

9.  Periodontal disease in patients with ankylosing spondylitis.

Authors:  N Pischon; T Pischon; E Gülmez; J Kröger; P Purucker; B-M Kleber; H Landau; P-G Jost-Brinkmann; P Schlattmann; J Zernicke; G-R Burmester; J-P Bernimoulin; F Buttgereit; J Detert
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

10.  Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study.

Authors:  M Dougados; S vam der Linden; M Leirisalo-Repo; B Huitfeldt; R Juhlin; E Veys; H Zeidler; T K Kvien; I Olivieri; B Dijkmans
Journal:  Arthritis Rheum       Date:  1995-05
View more
  2 in total

1.  Periodontal condition is associated with disease duration and motoric disabilities in patients with ankylosing spondylitis: results of a cross-sectional study.

Authors:  Dirk Ziebolz; David Douglas; Donya Douglas; Jan Schmickler; Daniel Patschan; Gerhard A Müller; Rainer Haak; Jana Schmidt; Gerhard Schmalz; Susann Patschan
Journal:  Rheumatol Int       Date:  2018-03-20       Impact factor: 2.631

2.  Reactive Arthritis Resulting From Postoperative Complications of Third Molar Extraction: A Case Report.

Authors:  Lauren Maytin; Jeffrey Morrison
Journal:  Cureus       Date:  2022-08-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.